吸入用左旋多巴（CVT-301）治疗帕金森病：随机对照试验的系统评价和荟萃分析
Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
作者信息
Glenardi Glenardi, Handayani Tutwuri, Barus Jimmy, Mangkuliguna Ghea
机构信息
School of Medicine and Health Sciences (GG, GM), Atma Jaya Catholic University of Indonesia, North Jakarta; Department of Neurology (TH), Syamsudin Hospital, Sukabumi, Indonesia; and Department of Neurology (JB), School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, North Jakarta.
出版信息
Neurol Clin Pract. 2022 Apr;12(2):139-148. doi: 10.1212/CPJ.0000000000001143.
PURPOSE OF REVIEW
To investigate the efficacy and safety of CVT-301 in treating motor fluctuation in patients with Parkinson disease (PD).
RECENT FINDINGS
This study demonstrated that the CVT-301 group had a higher proportion of patients achieving an ON state than the placebo group (odds ratio [OR] = 2.68; 95% confidence interval [CI]: 1.86-3.86; < 0.00001). Moreover, CVT-301 had also shown to improve motor function by Unified Parkinson Disease Rating Scale part III score (standardized mean difference = 3.83; 95% CI: 2.44-5.23; < 0.00001) and promote an overall improvement of PD by Patient Global Impression of Change self-rating (OR = 2.95; 95% CI: 1.78-4.9; < 0.00001). The most common adverse events encountered were respiratory symptoms (OR = 12.18; 95% CI: 5.01-29.62; < 0.00001) and nausea (OR = 3.95; 95% CI: 1.01-15.41; = 0.05).
SUMMARY
CVT-301 had the potential to be an alternative or even a preferred treatment for motor fluctuation in patients with PD.
综述目的
研究CVT - 301治疗帕金森病（PD）患者运动波动的疗效和安全性。
最新研究结果
该研究表明，CVT - 301组达到“开”状态的患者比例高于安慰剂组（优势比[OR]=2.68；95%置信区间[CI]：1.86 - 3.86；P<0.00001）。此外，CVT - 301还通过帕金森病统一评分量表第三部分评分改善了运动功能（标准化平均差=3.83；95%CI：2.44 - 5.23；P<0.00001），并通过患者整体变化印象自评促进了PD的整体改善（OR = 2.95；95%CI：1.78 - 4.9；P<0.00001）。最常见的不良事件是呼吸道症状（OR = 12.18；95%CI：5.01 - 29.62；P<0.00001）和恶心（OR = 3.95；95%CI：1.01 - 15.41；P = 0.05）。
总结
CVT - 301有可能成为PD患者运动波动的替代甚至首选治疗方法。
Zotero 插件